Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: Indirect evidence for islet regeneration?

J. J. Meier, A. Bhushan, A. E. Butler, R. A. Rizza, P. C. Butler

Research output: Contribution to journalArticle

345 Citations (Scopus)

Abstract

Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells. However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction. The aim of the present study was to evaluate these possibilities. Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages. The presence and extent of periductal fibrosis was also quantified. Results: Beta cells were identified in 88% of individuals with type 1 diabetes. The number of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose. Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups. The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells. Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed. The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity. The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes. We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.

Original languageEnglish (US)
Pages (from-to)2221-2228
Number of pages8
JournalDiabetologia
Volume48
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Type 1 Diabetes Mellitus
Regeneration
Apoptosis
Fibrosis
Macrophages
T-Lymphocytes
Insulin-Secreting Cells
Autoimmunity
Blood Glucose
Cell Death
Cell Count
Insulin
Inflammation
Glucose

Keywords

  • Autoimmunity
  • Beta cell apoptosis
  • Insulin secretion
  • Islet regeneration
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Sustained beta cell apoptosis in patients with long-standing type 1 diabetes : Indirect evidence for islet regeneration? / Meier, J. J.; Bhushan, A.; Butler, A. E.; Rizza, R. A.; Butler, P. C.

In: Diabetologia, Vol. 48, No. 11, 11.2005, p. 2221-2228.

Research output: Contribution to journalArticle

Meier, J. J. ; Bhushan, A. ; Butler, A. E. ; Rizza, R. A. ; Butler, P. C. / Sustained beta cell apoptosis in patients with long-standing type 1 diabetes : Indirect evidence for islet regeneration?. In: Diabetologia. 2005 ; Vol. 48, No. 11. pp. 2221-2228.
@article{a24bbba515774c8b8a81ce8043ca3a90,
title = "Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: Indirect evidence for islet regeneration?",
abstract = "Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells. However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction. The aim of the present study was to evaluate these possibilities. Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages. The presence and extent of periductal fibrosis was also quantified. Results: Beta cells were identified in 88{\%} of individuals with type 1 diabetes. The number of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose. Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups. The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells. Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed. The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity. The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes. We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.",
keywords = "Autoimmunity, Beta cell apoptosis, Insulin secretion, Islet regeneration, Type 1 diabetes",
author = "Meier, {J. J.} and A. Bhushan and Butler, {A. E.} and Rizza, {R. A.} and Butler, {P. C.}",
year = "2005",
month = "11",
doi = "10.1007/s00125-005-1949-2",
language = "English (US)",
volume = "48",
pages = "2221--2228",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Sustained beta cell apoptosis in patients with long-standing type 1 diabetes

T2 - Indirect evidence for islet regeneration?

AU - Meier, J. J.

AU - Bhushan, A.

AU - Butler, A. E.

AU - Rizza, R. A.

AU - Butler, P. C.

PY - 2005/11

Y1 - 2005/11

N2 - Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells. However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction. The aim of the present study was to evaluate these possibilities. Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages. The presence and extent of periductal fibrosis was also quantified. Results: Beta cells were identified in 88% of individuals with type 1 diabetes. The number of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose. Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups. The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells. Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed. The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity. The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes. We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.

AB - Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells. However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction. The aim of the present study was to evaluate these possibilities. Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages. The presence and extent of periductal fibrosis was also quantified. Results: Beta cells were identified in 88% of individuals with type 1 diabetes. The number of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose. Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups. The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells. Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed. The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity. The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes. We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.

KW - Autoimmunity

KW - Beta cell apoptosis

KW - Insulin secretion

KW - Islet regeneration

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=27744603796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744603796&partnerID=8YFLogxK

U2 - 10.1007/s00125-005-1949-2

DO - 10.1007/s00125-005-1949-2

M3 - Article

C2 - 16205882

AN - SCOPUS:27744603796

VL - 48

SP - 2221

EP - 2228

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 11

ER -